DOCSLIB.ORG

Pure Pricing List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pure Pricing List Product Name/Description Typical Directions 0.3cc Insulin Syringe UAD 0.5cc Insulin Syringe UAD 1cc Insulin Syringe UAD 1mL Syringe with 27g x 1/2" needle UAD Amlexanox 40mg Capsules 1 po QD Ammonium Tetrathiomolybdate 50mg Capsule 1 po BID AOD 9604 600mcg Capsule 1 po QD 0.25mL (300mcg) SQ QD 30 minutes before AOD 9604 1200mcg/mL Injection breakfast OR QHS on empty stomach AOD 9604 600mcg/mL Transdermal Cream Apply topically QD AOD 9604 600mcg/mL Transdermal Cream Apply topically QD AOD/BPC 2mg/2mg Cream Apply topically QD to wound AOD/BPC 2mg/2mg Cream Apply topically QD to wound ARA 290 4mg/mL Injection 0.5mL-1mL (2-4mg) SQ QD Ascorbic Acid 500mg/mL As directed BPC-157 500mcg Capsules 1 po QD BPC-157 500mcg Mini-Troche 1 SL QD BPC-157 2mg/mL Cream Apply topically QD BPC-157 2000mcg/mL Injection 0.25mL (500mcg) SQ QD BPC-157 200mcg/mL Eye Drops 1 drop into affected eye(s) BID 1 spray (200mcg) into one nostril QD **Alternate BPC-157 200mcg/0.1mL Nasal Spray nostrils QD** 1 spray (500mcg) into one nostril QD-BID BPC-157 500mcg/0.1mL Nasal Spray **Alternate nostrils QD** BPC-157/ Synapsin 5mg/50mg/mL 1 spray into one nostril 2-3 times daily BPC-157 1mg/mL Oral Paste Use to brush teeth 1-2 times daily BPC-157/GHK-Cu 2mg/2mg/mL Topical Cream Apply topically QD to wound 0.05mL (100mcg) SQ QHS 5 nights on, 2 nights CJC/Ipamorelin 2000mcg/2000mcg Injection off (Increase GH, sleep)… 0.05mL 3-4 times daily 5 days on, 2 days off (weight loss) 0.05mL (100mcg) SQ QHS 5 nights on, 2 nights CJC/Ipamorelin 2000mcg/2000mcg Injection off (Increase GH, sleep)… 0.05mL 3-4 times daily 5 days on, 2 days off (weight loss) 12425 Old Meridian, STE B-3 Carmel, IN 46032 PH: 317.740.1856 I FX: 866.401.4916 Qty Price Indication 1 $0.15 N/A 1 $0.15 N/A 1 $0.15 N/A 1 $0.25 N/A 1 $1.00 Insulin Resistance 1 $1.15 Decrease Copper, Cancer 1 $5.00 Osteoarthritis 5mL $150.00 Weight Loss 15mL $100.00 Anti-Aging 30mL $150.00 Anti-Aging 15gm $125.00 Wound Repair 30gm $250.00 Wound Repair 7.5mL $175.00 Sarcodoisis/Neuropathy 50mL $39.00 IV Vitamin 1 $2.50 Gut Repair 1 $2.50 Gut Repair 30mL $120.00 Wound Repair Regeneration/Neurotransmit 5mL $150.00 ter Support 10mL $99.00 Repair Regeneration/Neurotransmit 3mL $69.00 ter Support Regeneration/Neurotransmit 6mL $89.00 ter Support Regeneration/Neurotransmit 9mL $120.00 ter Support 30mL $150.00 Oral Health 15mL $100.00 Wound Repair Increase Growth Hormone/ 2mL $120.00 Weight Loss Increase Growth Hormone/ 5mL $300.00 Weight Loss CJC/Ipamorelin/IGF-Lr3 1.25mg/2.5mg/100mcg 0.2mL SQ QAM CJC/Ipamorelin 200mcg/200mcg/mL Transdermal Apply topically QD Cream DiHexa 5mg Capsule 1 po QD DiHexa 10mg Capsule 1 po QD DiHexa 20mg Capsule 1 po QD 0.25mL-1mL (5-20mg) topically to back of neck DiHexa 20mg/mL Transdermal Cream QD, 5 days on, 2 days off 0.25mL-1mL (5-20mg) topically to back of neck DiHexa 20mg/mL Transdermal Cream QD, 5 days on, 2 days off 0.25mL-1mL (5-20mg) topically to back of neck DiHexa 20mg/mL Transdermal Cream QD, 5 days on, 2 days off DSIP 1000mcg/mL 0.1mL (100mcg) SQ QHS 3 times weekly DSIP 1000mcg/mL 0.1mL (100mcg) SQ QHS 3 times weekly DSIP/Glycine 1mg/10mg/mL 0.1mL (100mcg) SQ QHS 3 times weekly Epitalon 3000mcg/mL 0.1mL (300mcg) SQ HS for sleep Epitalon 10mg/mL 1mL (10mg) SQ QD for 20 days 2-3 times yr Epithalon Eye Drops 4mg/mL 1 drop into affected eye(s) BID 5mcg SQ BID initially, May increase to 10mcg SQ Exenatide 100mcg/mL BID 0.1-0.5mL (1-5mg) SQ QD 5 days on, 2 days off FGL 10mg/mL Injection (unavailable currently) for 4-6 weeks Genetic Test N/A GHK-Cu 2mg/mL Cream Apply topically to scalp QD GHK-Cu 5mg/mL Spray Apply topically to scalp QD for hair growth GHK-Cu 5mg/mL Dropper Apply topically to scalp QD for hair growth GHK-Cu 5mg/mL Foam Apply topically to scalp QD for hair growth GHK-Cu 10mg/mL Injection 0.2mL SQ QD GHK-Cu/Argireline/Leuphasyl 0.2%/10%/5% Cream Apply to wrinkles 1-2 times daily or Gel GHK-Cu/Hyaluronic Acid 2/10mg/mL Cream Apply topically QD to wound Gonadorelin To be determined IGF-1/ LR3 1000mcg/mL As directed Ipamorelin 2000mcg/mL As directed Ipamorelin 2000mcg/mL As directed iRGD 2500mcg/mL As directed Kisspeptin 1000mcg/mL 0.1mL (100mcg) QD KPV 2mg/mL Injection As directed Increase Growth Hormone/ 6mL $195.00 Weight Loss 30gm $200.00 N/A 1 $2.00 Neurocognitive 1 $4.00 Neurocognitive 1 $8.00 Neurocognitive 10mL $110.00 Neurocognitive 20mL $160.00 Neurocognitive 30mL $210.00 Neurocognitive 3mL $69.00 Circadium Rythym/Sleep 5mL $115.00 Circadium Rythym/Sleep 5mL $135.00 Circadium Rythym/Sleep 5mL $225.00 Sleep Immune (Increase 5mL $250.00 Telomeres) 3mL $150.00 Eye repair 5mL $100.00 Insulin Resistance 5mL $240.00 Neurocognitive 1 $200.00 N/A 30gm $80.00 Hair Restoration 30mL $60.00 Hair Restoration 30mL $60.00 Hair Restoration 50mL $65.00 Hair Restoration 5mL $180.00 Hair Restoration 30mL $75.00 Anti-Aging/Wrinkles 15mL $55.00 Wounds To be determined Increase Growth Hormone/ 2.5mL $150.00 Weight Loss Increase Growth 2mL $80.00 Hormone/Weight Loss Increase Growth 5mL $150.00 Hormone/Weight Loss Cancer- Increase drug into 10mL $130.00 C cells Testosterone Alternative 5mL $135.00 (Increases LH) 5mL $150.00 Anti-Inflammatory/Immune KPV 500mcg Acid Resistant Capsule 1 po QD KPV 1mg/mL Cream Apply topically to affected area(s) QD KPV 500mcg/0.1mL Nasal Spray 1 spray into one nostril BID KPV 500mcg/BPC-157 500mcg AR Capsule 1 po QD Larazotide 500mcg 1 po QD 0.1mL (200mcg) SQ QD **Max 6 weeks**, 0.2-0.3 LL-37 2000mcg/mL Injection mL SQ BID X 7-10 days Melanotan II 2000mcg/mL 0.25mL (500mcg) SQ twice weekly 0.15mL (300mcg) SQ QD x 2 weeks, then 0.25 Melanotan II 2000mcg/mL mL (500mcg) twice weekly Minoxidil/GHK-Cu 55mg/5mg/mL Apply topically QD to scalp for hair growth MK-677 (Ibutamoren) 12.5mg Capsule 1 po QD MK-677 (Ibutamoren) 25mg Capsule 1 po QD Inject 1mL (10mg) SQ once weekly for MOTs-C 10mg/mL maintenance NAD+ 200mg/mL Infuse UD PE 22-28 4mg/mL Nasal Spray 1 spray into each nostril QD **Alternate nostrils** Peg-MGF 2000mcg/mL (available soon!) 0.1mL SQ QD 5 days weekly Pentosan Polysulfate 250mg/mL As directed PT-141 10,000mcg/mL 0.1-0.2mL SQ 3 times weekly prn PT-141/B6 1,000mcg/10mg Troche 1-2 SL one hour prior to intimacy PT-141/B6 2,000mcg/10mg Troche 1 SL one hour prior to intimacy PT-141 1mg/0.1mL Nasal Spray 1 spray in nostril 30-60 min prior to intimacy PTD-DMB 0.001% Dropper Apply topically to scalp QD for hair growth PTD-DMB 0.001% Spray Apply topically to scalp QD for hair growth SeLANK 1000mcg/mL Injectable 0.1mL (750mcg) SQ QD SeLANK 750mcg/0.1mL Nasal Spray 1 spray into each nostril QD SeMAX 1000mcg/1mL Injectable 0.1mL (750mcg) SQ QD SeMAX 750mcg/0.1mL Nasal Spray 1 spray into each nostril QD 0.1mL SQ QD x 1 week, May increase to 0.15-0.2 Setmelanotide 1000mcg/mL mL QD As tolerated Sermorelin/Ipamorelin 4000mcg/2000mcg/mL Inject 0.1ml subcutaneously 5 out of 7 days Sermorelin 2000mcg/mL Shipping_Indiana [General] N/A Shipping_Indiana [Refrigerated] N/A Shipping Out of State_Residential N/A Shipping_Overnight N/A Sirolimus 2.5mg 1 po QD x 2 weeks, then one day per week 1 $3.00 Anti-Inflammatory/Immune 30mL $85.00 Psoriasis 6mL $85.00 Neuroinflammation Gut Repair/Anti- 1 $5.00 Inflammatory/Immune Phase 3 clinical trial for 1 $4.00 Celiac Disease Anti-Microbial (Lyme's, 5mL $100.00 Influenza) 2mL $48.00 Libido/Tanning 5mL $100.00 Libido/Tanning 30 $60.00 Hair Restoration 1 $2.50 Weight Loss/Muscle Growth 1 $5.00 Weight Loss/Muscle Growth 5mL $300.00 Mitochondria Peptide 10mL $89.00 Various 6mL $75.00 Anti-Depressant 5mL $180.00 Muscle Growth 5mL $69.00 Immune/ Osteoarthritis 2mL $100.00 Libido/Sexual Dysfunction 1 $2.50 Libido/Sexual Dysfunction 1 $5.00 Libido/Sexual Dysfunction 5 $115.00 Libido/Sexual Dysfunction 25mL $60.00 Hair Restoration 25mL $60.00 Hair Restoration 5mL $90.00 Neurocognitive (anxiety) 3mL $39.00 Neurocognitive (anxiety) 5mL $90.00 Neurocognitive (focus) 3mL $39.00 Neurocognitive (focus) Weight Loss (MC4R 5mL $150.00 agonist) 2.5mL $85.00 Weight Loss 7.5mL $95.00 Weight Loss 1 $3.99 N/A 1 $9.99 N/A 1 $25.00 N/A 1 $50.00 N/A 1 $3.00 Increase Autophagy SS-31 50mg/mL 1mL (50mg) SQ twice weekly Inject 0.4mL SQ QD 6 days per week on empty Tesamorelin 2500mcg/mL stomach Thymosin Alpha 1 3000mcg/mL Injection 0.15mL (450mcg) SQ QD Thymosin Beta 4 3000mcg/mL Injection 0.25mL (750mcg) SQ QD Thymosin Beta 4 0.1% Eye Drop 1 drop into affected eye(s) BID Apply to scalp QD after PTD-DBM application and Valproic Acid 5% or 8.3% Spray derma roller VIP 500mcg/mL 1 spray into each nostril BID Zinc-Thymulin 0.001% Spray Apply topically to scalp QD for hair growth Zinc-Thymulin 0.001% Foam Apply topically to scalp QD for hair growth Zinc-Thymulin/GHK-Cu 10mcg/5mg/mL Dropper Apply topically to scalp QD for hair growth Zinc-Thymulin/GHK-Cu 10mcg/5mg/mL Spray Apply topically to scalp QD for hair growth 5mL $325.00 Mitochondria Peptide Increase Growth Hormone/ 10mL $300.00 Wt Loss/ Muscle Growth 5mL $150.00 Immune 5mL $150.00 Immune/Repair 3mL $150.00 Immune/Repair/Dry Eyes 25mL $39.00 Hair Restoration 12mL $99.00 Mold Toxicity 30mL $59.00 Hair Restoration 50mL $59.00 Hair Restoration 30mL $69.00 Hair Restoration 30mL $69.00 Hair Restoration.
Load more

Recommended publications
  • Preclinical Effects of Melanocortins in Male Sexual Dysfunction
    International Journal of Impotence Research (2008) 20, S11–S16 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir Preclinical effects of melanocortins in male sexual dysfunction AM Shadiack1 and S Althof2 1Locus Pharmaceuticals, Blue Bell, PA, USA and 2The Center for Marital and Sexual Health of South Florida, West Palm Beach, FL, USA The neurobiology of sexual behavior involves the interrelationships between sex steroids and neurotransmitters that result in both central nervous system (CNS) effects and effects in the genitalia. Tools such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scanning can help determine what areas of the brain are activated under sexual stimulation. Our understanding of the role of various neurotransmitters, neurosteroids and other CNS-acting compounds is improving. The role of CNS-acting compounds such as dopamine agonists in the treatment of male sexual dysfunction is under active investigation. Melanocortins have CNS and peripheral roles in a wide variety of bodily functions. The melanocortin agonist bremelanotide appears to act in the CNS to promote erections in preclinical models, and may also stimulate behaviors that facilitate sexual activity beyond their erectogenic effects. International Journal of Impotence Research (2008) 20, S11–S16; doi:10.1038/ijir.2008.17 Keywords: erectile dysfunction; neuroanatomy; neurophysiology; CNS-acting agents; melanocortins; bremelanotide Introduction Neuroanatomy of male sexual response The neurobiology of sexual behavior involves the Sex and the brain interrelationships between sex steroids and neuro- Sexual arousal can now be studied with such transmitters that result in both central nervous sophisticated tools as PET (positron emission system (CNS) effects and effects in the genitalia.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0051633 A1 Harding Et Al
    US 20140051633A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0051633 A1 Harding et al. (43) Pub. Date: Feb. 20, 2014 (54) HEPATOCYTE GROWTH FACTOR MIMICS (60) Provisional application No. 61/706,567, filed on Sep. AS THERAPEUTICAGENTS 27, 2012, provisional application No. 61/706,437, filed on Sep. 27, 2012. (71) Applicant: Washington State University, Pullman, WA (US) Publication Classification (72) Inventors: Joseph W. Harding, Pullman, WA (US); John W. Wright, Pullman, WA (US); (51) Int. C. Caroline C. Benoist, Nashville, TN C07K5/065 (2006.01) (US); Leen H. Kawas, Pullman, WA (52) U.S. C. (US); Gary A. Wayman, Pullman, WA CPC .................................. C07K5/06078 (2013.01) (US) USPC ........................................................... S14/95 (73) Assignee: Washington State University, Pullman, WA (US) (57) ABSTRACT (21) Appl. No.: 14/038,973 (22) Filed: Sep. 27, 2013 Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been gen Related U.S. Application Data erated. These molecules have been shown or predicted to have (63) Continuation-in-part of application No. PCT/US2012/ therapeutic potential for numerous pathologies including 031815, filed on Apr. 2, 2012. dementia (e.g. Alzheimer's) and Parkinson's disease. Patent Application Publication Feb. 20, 2014 Sheet 1 of 40 US 2014/0051633 A1 a --- --- - - -s ------- CS -8- Scopolarine s -k- Oii exa-ow " -: N. Sks s i. Y s re. Dihexa-high as: ^ N.-- st-scs:- -------------------------------------------------------------------------------------------. Acquisition (days) Figure 1A -8-CSF -- -8- Scopoanine i. --- - -k- Dihexa-ow -- hexa-high reta-or 2 3 4 5 6 7 8 Acquisition (days) Figure 1B -8- vici-treated -- hexa Acquisition (days) Figure 1C Patent Application Publication Feb.
    [Show full text]
  • Counteracting EMF Toxicity with Peptides (Forget Global Warming Emfs Are Killing Us)
    Counteracting EMF Toxicity with Peptides (Forget Global Warming EMFs are Killing Us) Dr. Kent Holtorf, MD Medical Director/CEO, Holtorf Medical Group (HoltorfMed.com) Medical Director/CEO, National Academy of Hypothyroidism (NAHypothyroidism.org) Medical Director, Integrative Peptides (IntegrativePeptides.com) Disclosure Statement Owner/CEO - Holtorf Medical Group HoltorfMed.com A multi-specialty medical group specializing in the treatment of complex endocrine dysfunction, CFS/fibromyalgia, chronic infectious diseases, immune dysfunction, neurodegenerative disease, and other complex chronic illnesses. Chief Medical Officer - The Non-Profit, The National Academy of Hypothyroidism and Integrative Sciences (NAHIS) NAHypothyroidism.org NAHIS is a non- profit, multidisciplinary medical society dedicated to the dissemination of new information on the diagnosis and treatment of hypothyroidism and complex conditions. NAHIS receives grants for clinical and laboratory research for novel methods in the diagnosis and treatment of hypothyroidism and chronic illnesses Chief Medical Officer - Integrative Peptides IntegrativePeptides.com Currently sells orally active and absorbable natural peptides in oral supplement form with unique delivery methods 2 Disclosure Statement Important Disclaimer In the interest of full disclosure, I am the All studies have limitations, and there is no perfect study. As with other studies, the studies Chief Medical Officer of Integrative Peptides. mentioned in this presentation and during the summit have limitations that should be considered when evaluating the efficacy of any treatment, including peptides, and determining the The opinions expressed are mine and do not appropriateness of peptide therapy for consumer use. A short summary, the abstract or reference to necessarily reflect those of Integrative a study may be discussed or provided. We are happy to provide you the entire study for your review of any study discussed, mentioned, presented or referenced.
    [Show full text]
  • PEPTIDE INFORMATION Contact Kitt Burkley for Pricing 855-762-4878
    PEPTIDE INFORMATION Contact Kitt Burkley for pricing 855-762-4878 AOD 9604 AOD 9604 works by mimicking the way natural HGH regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified HGH. Studies have suggested that AOD 9604 has an ability to stimulate lipolysis and inhibit lipogenesis. In addition AOD 9604 possesses other regenerative properties associated with growth hormone. Trials have been undertaken to determine the possible application of AOD 9604 in osteoarthritis and hypercholesterolemia, as well as for bone and cartilage repair. Results of oral glucose tolerance testing have demonstrated that AOD 9604 has no negative effect on carbohydrate metabolism, and it does not affect serum IGF-1 levels. AOD 9604 has an excellent safety profile and is generally well tolerated. It has attained Human GRAS status in the US. AOD 9604 600mcg/ml Cream – 30g AOD 9604* 0.5mg Troche BPC-157 (Body Protection Compound) BPC-157 promotes muscle and tendon healing, increases angiogenesis and decreases inflammatory response. Produces more type 1 collagen and has excellent potential for diabetic wound healing. BPC- 157 is highly stable, resistant to both hydrolysis and enzyme digestion. It can be given orally as well as administered subcutaneously or intramuscularly – no carrier molecule is required. This peptide has significant anti-inflammatory modulating effects. BPC-157 promotes tissue healing through signaling pathways – it provides specific response to particular injury thru cell signaling. BPC- 157 can be used continuously as body protective, or for specific period to treat body injury. BCP-157 is in clinical trials for IBD.
    [Show full text]
  • Pharmacological Chaperone Action in Humanized Mouse Models of MC4R-Linked Obesity
    Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity Patricia René, … , Denis Richard, Michel Bouvier JCI Insight. 2021;6(4):e132778. https://doi.org/10.1172/jci.insight.132778. Technical Advance Metabolism Therapeutics MC4R mutations represent the largest monogenic cause of obesity, resulting mainly from receptor misfolding and intracellular retention by the cellular quality control system. The present study aimed at determining whether pharmacological chaperones (PCs) that restore folding and plasma membrane trafficking by stabilizing near native protein conformation may represent valid therapeutic avenues for the treatment of melanocortin type 4 receptor–linked (MC4R- linked) obesity. To test the therapeutic PC potential, we engineered humanized MC4R (hMC4R) mouse models expressing either the WT human MC4R or a prevalent obesity-causing mutant (R165W). Administration of a PC able to rescue cell surface expression and functional activity of R165W-hMC4R in cells restored the anorexigenic response of the R165W-hMC4R obese mice to melanocortin agonist, providing a proof of principle for the therapeutic potential of MC4R- targeting PCs in vivo. Interestingly, the expression of the WT-hMC4R in mice revealed lower sensitivity of the human receptor to α–melanocyte-stimulating hormone (α-MSH) but not β-MSH or melanotan II, resulting in a lower penetrance obese phenotype in the WT-hMC4R versus R165W-hMC4R mice. In conclusion, we created 2 new obesity models, a hypomorphic highlighting species differences and an amorphic providing a preclinical model to test the therapeutic potential of PCs to treat MC4R-linked obesity. Find the latest version: https://jci.me/132778/pdf TECHNICAL ADVANCE Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity Patricia René,1 Damien Lanfray,2 Denis Richard,2 and Michel Bouvier1 1Départment de Biochimie et de Médecine Moléculaire, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec, Canada.
    [Show full text]
  • Zebrafish Bioassay for Screening Therapeutic Candidates Based On
    International Journal of Molecular Sciences Article Zebrafish Bioassay for Screening Therapeutic Candidates Based on Melanotrophic Activity Ted I. Hong 1,†, Kyu-Seok Hwang 2,† , Tae-Ik Choi 1, Gunnar Kleinau 3, Patrick Scheerer 3 , Jeong Kyu Bang 4 , Seung-Hyun Jung 5,* and Cheol-Hee Kim 1,* 1 Department of Biology, Chungnam National University, Daejeon 34134, Korea; [email protected] (T.I.H.); [email protected] (T.-I.C.) 2 Drug Discovery Platform Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea; [email protected] 3 Group Protein X-ray Crystallography and Signal Transduction, Institute of Medical Physics and Biophysics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, D-10117 Berlin, Germany; [email protected] (G.K.); [email protected] (P.S.) 4 Division of Magnetic Resonance, Korea Basic Science Institute, Ochang, Cheongju 28119, Korea; [email protected] 5 Department of Applied Marine Bioresource Science, National Marine Biodiversity Institute of Korea, Seocheon 33662, Korea * Correspondence: [email protected] (S.-H.J.); [email protected] (C.-H.K.) † These authors contributed equally to this work. Abstract: In this study, we used the zebrafish animal model to establish a bioassay by which physi- ological efficacy differential of alpha-melanocyte-stimulating hormone (α-MSH) analogues could be measured by melanosome dispersion in zebrafish larvae. Brain-skin connection research has Citation: Hong, T.I.; Hwang, K.-S.; purported the interconnectedness between the nervous system and skin physiology. Accordingly, the Choi, T.-I.; Kleinau, G.; Scheerer, P.; neuropeptide α-MSH is a key regulator in several physiological processes, such as skin pigmentation Bang, J.K.; Jung, S.-H.; Kim, C.-H.
    [Show full text]
  • Targeting Central Melanocortin Receptors: a Promising Novel Approach for Treating Alcohol Abuse Disorders
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector REVIEW ARTICLE published: 03 June 2014 doi: 10.3389/fnins.2014.00128 Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders Jeffrey J. Olney 1, Montserrat Navarro 1 and Todd E. Thiele 1,2* 1 Department of Psychology, University of North Carolina, Chapel Hill, NC, USA 2 Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC, USA Edited by: The melanocortin (MC) peptides are produced centrally by propiomelanocortin (POMC) Richard Lowell Bell, Indiana neurons within the arcuate nucleus of the hypothalamus and act through five University School of Medicine, USA seven-transmembrane G-protein coupled melanocortin receptor (MCR) subtypes. The Reviewed by: MC3R and MC4R subtypes, the most abundant central MCRs, are widely expressed Gregg E. Homanics, University of Pittsburgh, USA in brain regions known to modulate neurobiological responses to ethanol, including Luigia Trabace, University of Foggia, regions of the hypothalamus and extended amygdala. Agouti-related protein (AgRP), Italy also produced in the arcuate nucleus, is secreted in terminals expressing MCRs and Olivier George, The Scripps functions as an endogenous MCR antagonist. This review highlights recent genetic and Research Institute, USA pharmacological findings that have implicated roles for the MC and AgRP systems in *Correspondence: Todd E. Thiele, Department of modulating ethanol consumption. Ethanol consumption is associated with significant Psychology, University of North alterations in the expression levels of various MC peptides/protein, which suggests that Carolina, Davie Hall, CB #3270, ethanol-induced perturbations of MC/AgRP signaling may modulate excessive ethanol Chapel Hill, NC 27599-3270, USA intake.
    [Show full text]
  • Professional Monograph Melanotan II
    Professional Monograph Melanotan II SUMMARY ● Meltanotan II - synthetic alpha melanocyte stimulating hormone (α -MSH) ​ ​ ● Non-specific central melanocortin receptor agonist – MC1R, MC3R, MC4R, MC5R ● Melanotan I (afamelanotide) has the same mechanism of action as Melantotan II, however Melanotan I doesn’t cross the BBB so no central effects (the metabolism support and sexual stimulation) like Melanotan II ● Supports melanogenesis ● Photoprotective ● Improves libido ● Immune – activates Treg cells and improves Th1/Th17 balance ● Reduces appetite and improves lipid and glucose regulation ● Neuroprotective – decreases neuroinflammation © Copyright 2018, Scientific Performance Research, LLC" Cincinnati, OH ● Dopamine modulating Uses ● Tanning ● Protection from phototoxicity o Erythropoietic protoporphyria ● Metabolic Support o Lipolytic, appetite control, anti-inflammatory, decreases oxidative stress ● Conditions requiring immune balance o Autoimmune conditions ● Libido enhancement ● Potential use in alcohol and drug abuse, including opioids, cocaine (reward cascade supportive) DOSAGE ● General dosage o Tanning ▪ 200 mcg SubQ daily for 1 week ▪ Adjust according to pigment changes ▪ After pigment stabilizes, 100 mcg SC 2 x a week o Metabolic Enhancement ▪ 50 mcg daily SubQ and adjust o Immunity ▪ 200 mcg daily SubQ for 6-8 weeks ▪ Use until clinical effects are pronounced o Sexual stimulation ▪ More of a Side effect so occurs with any dosage regimen ▪ Higher doses (ie 500 – 1,000 mcg) can lead to more pronounced stimulation ▪ Melanotan sexual
    [Show full text]
  • Resolution Pharmacology Therapeutic Innovation in Inflammation.ACTH: the Forgotten Therapy Trinidad Montero-Melendez the William
    Resolution Pharmacology therapeutic innovation in inflammation.ACTH: The Forgotten Therapy Trinidad Montero-Melendez The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London. Charterhouse Square, EC1M 6BQ, London, United Kingdom. Correspondence: Trinidad Montero-Melendez, PhD Address: The William Harvey Research Institute, Barts and The London School of Medicine, Charterhouse Square, EC1M 6BQ, London, United Kingdom. Telephone: +44-207-8825654 Fax: +44-207-8826076 E-mail: [email protected] Abstract Although anti-inflammatory drugs are among the most common class of marketed drugs, chronic inflammatory conditions such as rheumatoid arthritis, multiple sclerosis or inflammatory bowel disease still represent unmet needs. New first-in-class drugs might be discovered in the future but the repurpose and further development of old drugs also offers promise for these conditions. This is the case of the melanocortin adrenocorticotropin hormone, ACTH, used in patients since 1952 but regarded as the last therapeutic option when other medications, such as glucocorticoids, cannot be used. Better understanding on its physiological and pharmacological mechanisms of actions and new insights on melanocortin receptors biology have revived the interest on rescuing this old and effective drug. ACTH does not only induce cortisol production, as previously assumed, but it also exerts anti-inflammatory actions by targeting melanocortin receptors present on immune cells. The endogenous agonists for these receptors (ACTH, α-, β-, and γ-melanocyte stimulating hormones), are also produced locally by immune cells, indicating the existence of an endogenous anti-inflammatory tissue-protective circuit involving the melanocortin system. These findings suggested that new ACTH-like melanocortin drugs devoid of steroidogenic actions, and hence side effects, could be developed.
    [Show full text]
  • Unabated Anorexic and Enhanced Thermogenic Responses to Melanotan II in Diet-Induced Obese Rats Despite Reduced Melanocortin 3 and 4 Receptor Expression
    123 Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression GLi1, Y Zhang1,2, J T Wilsey1,2 and P J Scarpace1,2 1Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida 32610, USA 2Geriatric Research, Education and Clinical Center (182), Department of Veterans Affairs Medical Center, Gainesville, Florida 32608-1197, USA (Requests for offprints should be addressed to P J Scarpace, Geriatric Research, Education and Clinical Center, Malcolm Randall Veterans Affairs Medical Center, Gainesville, Florida 32608-1197, USA; Email: scarpace@ufl.edu) Abstract The effects of the chronic activation of the central melano- expression and prevented the reduction in muscle-type cortin (MC) system by melanotan II (MTII) were assessed carnitine palmitoyltransferase I mRNA by pair-feeding in in chow-fed (CH) and high-fat (HF) diet-induced obese the muscle of DIO rats. Compared with CH controls, (DIO) Sprague–Dawley rats. Six-day central infusion of hypothalamic MC3 and MC4 receptor expression levels MTII (1 nmol/day) reduced body weight and visceral were reduced in DIO controls. This study has demon- adiposity compared with ad libitum-fed control and pair- strated that, despite reduced hypothalamic MC3/MC4 fed groups and markedly suppressed caloric intake in both receptor expression, anorexic and thermogenic responses CH and DIO rats. The anorexic response to MTII was to MTII are unabated with an initial augmentation of similar in DIO relative to CH rats. MTII induced a energy expenditure in DIO versus CH rats. The HF- sustained increase in oxygen consumption in DIO but a induced up-regulation of UCP1 in BAT may contribute delayed response in CH rats.
    [Show full text]
  • Supplementary Data
    Supplementary data Table S1. Results of the docking of DrugBank compounds onto GRP78 (NBD) (only molecules with lower docking scores than control ATP are presented). Molecule name Final docking score S (kcal/mol) Imatinib -9.26206 FK-614 -8.9803 Selonsertib -8.85865 Sorafenib -8.841712 CID 5288250 -8.6442 Pemetrexed -8.6247129 4SC-203 -8.61179 Zafirlukast -8.59865 (2S)-2-[[4-[2-[(6S)-2-Amino-4-oxo-5,6,7,8-tetrahydro-3H-pyrido[2,3-d]pyrimidin- -8.58657 6-yl]ethyl]benzoyl]amino]pentanedioic acid Icariin -8.46474 Raltegravir -8.44994 4-[(5-{[4-(3-Chlorophenyl)-3-oxopiperazin-1-YL]methyl}-1H-imidazol-1- -8.44899 YL)methyl]benzonitrile Dacomitinib -8.4483 [(1S)-1-Cyclohexyloxycarbonyloxyethyl] 2-ethoxy-3-[[4-[2-(2H-tetrazol-5- -8.43484 yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate Darexaban -8.4267 Tenofovir disoproxil -8.4124937 Neratinib -8.39573 Ponatinib -8.38035 6-(3-(Dimethylcarbamoyl)phenylsulfonyl)-4-(3-methoxyphenylamino)-8- -8.32773 methylquinoline-3-carboxamide 2'-Deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen phosphate) -8.31957 3-(5-{[4-(Aminomethyl)piperidin-1-Yl]methyl}-1h-Indol-2-Yl)quinolin-2(1h)-One -8.30333 (2R)-N-[2-[4-[5-[4-[(4-Acetamidophenyl)methoxy]-2,3-dichlorophenyl]-2- -8.2941 methylpyrazol-3-yl]piperidin-1-yl]-2-oxoethyl]-2-(diaminomethylideneamino)- 4-methylpentanamide Butafenacil -8.29337 Nilotinib -8.28767 Gedatolisib -8.27715 N-(Sulfanylacetyl)tyrosylprolylmethioninamide -8.27166 Leucovorin -8.2563314 Asp3026 -8.24956 Methyl (1R,2S)-2-(hydroxycarbamoyl)-1-[[4-[(2-methylquinolin-4- -8.2435 yl)methoxy]phenyl]methyl]cyclopropane-1-carboxylate
    [Show full text]
  • Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole
    Neuropsychopharmacology (2015) 40, 1856–1865 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole *,1,2 1 1 1 2,3 Meera E Modi , Kiyoshi Inoue , Catherine E Barrett , Kara A Kittelberger , Daniel G Smith , 4 1 Rainer Landgraf and Larry J Young 1 Center Translational Social Neuroscience, Silvio O Conte Center for Oxytocin and Social Cognition, Department of Psychiatry and Behavioral 2 Sciences, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Neuroscience Research Unit, Pfizer Worldwide Research 3 4 and Development, Cambridge, MA, USA; Autism Speaks, Boston, MA, USA; Max Plank Institute of Psychiatry, Munich, Germany The central melanocortin (MC) system has been widely studied for its effects on food intake and sexual behavior. However, the MC system, and more specifically the MC4 receptor (MC4R), also interacts with neurochemical systems that regulate socioemotional behaviors, including oxytocin (OT) and dopamine. In monogamous prairie voles, OT and dopamine interact to promote partner preference formation, a laboratory measure of an enduring social bond between mates. Here we investigated the effects of MC receptor activation on partner preference formation in prairie voles, as well as the interaction between the MC and OT systems during this process. Peripheral administration of the brain penetrant MC3/4R receptor peptide agonist, Melanotan II (MTII), and the highly selective, small- molecule MC4R agonist, Pf-446687, enhanced partner preference formation in the prairie vole, but not in the non-monogamous meadow vole. MTII-induced partner preferences were enduring, as they were present 1 week after drug manipulation.
    [Show full text]